>
- for Healthcare Professionals >
- The EAU approach to non-muscle invasive bladder cancer treatment
The European Association of Urology regularly update their guidelines for the treatment of non-muscle invasive bladder cancer. These are based on the latest available clinical evidence.
Their latest guidelines (2013) recommend different treatments depending on how likely a patient’s cancer is to recur or progress.
Their main recommendations are:1
A single chemotherapy dose for low- or intermediate-risk patients
"One, immediate, post-operative intravesical instillation of chemotherapy."
Further chemotherapy or long-term BCG treatment for intermediate-risk patients
For patients with intermediate to high recurrence risk and intermediate progression risk "further instillations of chemotherapy or a minimum of one year of BCG."
Long-term BCG treatment or immediate cystectomy for high-risk patients
"Intravesical BCG for at least one year, or immediate cystectomy."
< Back | A single chemotherapy dose for low- or intermediate-risk patients > |